Teva Pharmaceuticals, Granules USA and Heritage Pharmaceuticals agreed to pay a combined $5.55 million class action settlement to resolve claims their metformin products were contaminated with cancer-causing N-nitrosodimethylamine (NDMA).<\/p>\n
The metformin class action settlement benefits consumers who paid for Teva, Granules or Heritage metformin products between July 20, 2015, and June 2, 2020.<\/p>\n
According to the class action lawsuit, Teva, Granules and Heritage manufactured metformin-containing drugs that were contaminated with NDMA, a probable human carcinogen. The products allegedly failed to meet the U.S. Food and Drug Administration standards for metformin.<\/p>\n
Metformin is a diabetes medication. Teva, Granules and Heritage manufactured generic versions of Glucophage and Glucophage XR, brand-name metformin products.<\/p>\n
The companies have not admitted any wrongdoing but agreed to a $5.55 million class action settlement to resolve the metformin-containing drugs class action lawsuit. Teva agreed to a $3 million settlement and Granules and Heritage have agreed to a $2.55 million settlement.<\/p>\n
Under the terms of the metformin settlement, class members can receive a cash payment based on how much they paid for metformin-containing drugs, with amounts varying depending on the number of claims filed and eligible purchase costs.<\/p>\n
The deadline for exclusion and objection is July 10, 2026.<\/p>\n
The final approval hearing for the Teva, Granules and Heritage metformin settlement is scheduled for Aug. 12, 2026.<\/p>\n
To receive settlement benefits, class members must submit a valid claim form by July 10, 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"Teva Pharmaceuticals, Granules USA and Heritage Pharmaceuticals agreed to pay a combined $5.55 million class action settlement to…\n","protected":false},"author":2,"featured_media":984612,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4315],"tags":[196824,105,4326,16,15],"class_list":["post-984611","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-featured-settlement","tag-health","tag-medication","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116637456820668899","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/984611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=984611"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/984611\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/984612"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=984611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=984611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=984611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}